Načítá se...
4CPS-135 Effectiveness and cost of eculizumab on patients with atypical (shua), urenic and haemolitic syndrome, with enlargement of the frequency of administration
BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is a thrombotic microangiopathy that primarily affects the kidney. PURPOSE: To compare the effectiveness and cost of eculizumab (monoclonal antibody indicated for the treatment of aHUS) on a patient on whom it is administered more frequently as...
Uloženo v:
| Vydáno v: | Eur J Hosp Pharm |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535341/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.226 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|